Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05295355
Other study ID # OCT-COPD
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 25, 2021
Est. completion date March 2025

Study information

Verified date October 2022
Source Guangzhou Institute of Respiratory Disease
Contact Shiyue Li, Doctor
Phone +86 13902233825
Email lishiyue@188.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

72 patients with mild to moderate chronic obstructive pulmonary disease were planned to be enrolled in this study and then treated with olodaterol combined with thiotropium bromide, and thiotropium bromide, respectively, for 52 weeks. To assess the effect of the test drug on small airway remodeling in patients.


Description:

Studies have confirmed that thiotropium bromide combined with olodaterol can significantly improve airway inflammation, quality of life and pulmonary function in patients with stable COPD, without significantly increasing adverse reactions, which is worthy of clinical promotion. At present, there are few reports on the effect of thiotropium combined with olodaterol on airway remodeling in COPD patients, so this randomized, double-blind, parallel-controlled, single-center clinical trial was designed to compare the long-term effects of thiotropium combined with olodaterol, and thiotropium on small airway remodeling in patients with mild to moderate chronic obstructive pulmonary disease. 72 patients with mild to moderate chronic obstructive pulmonary disease were planned to be enrolled in this study. After screening examination, eligible subjects were randomly assigned to the test group or the control group in a 1:1 ratio and received olodaterol combined with thiotropium bromide, and thiotropium bromide, respectively, for 52 weeks. The effect of the test drug on small airway remodeling was assessed at 12, 26, and 52 weeks after treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date March 2025
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Male or female, aged = 40 years; - Meet the diagnostic criteria of COPD, and GOLD grade I - II; - FEV1/FVC < 70% and FEV1 = 50% of the expected value after the use of bronchodilators; - Patients must be able to complete all study-related steps, voluntarily participate in this study and sign the informed consen. Exclusion Criteria: - Patients with asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, pulmonary embolism, bronchiolitis obliterans, paradoxical bronchospasm; - Patients with blood eosinophilia; - Patients with upper respiratory tract infection; - Patients with liver or renal insufficiency; - Patients with severe unstable systemic diseases or malignant tumors; - Patients with glaucoma, benign prostatic hyperplasia or bladder neck obstruction; - Patients with hypokalemia, hyperglycemia, diabetes, ketoacidosis or other serious systemic diseases such as heart, brain, liver, kidney, digestive system, endocrine system, immune system, blood; - Women of childbearing age who are pregnant, lactating or plan to become pregnant; - Patients who have undergone previous pneumonectomy or received lung volume reduction surgery within 12 months before screening; - Patients with mental illness; - Patients who have participated in other clinical trials within 3 months before screening; - Allergic constitution or known allergy to atropine or its derivatives (such as isopropylamine or oxytoluium) Or those who are allergic to the intervention drugs and their ingredients; - The researchers believe that it is not appropriate to participate in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tiotropium Bromide Combined With Odaterol
2 puffs once daily at the same time of the day for 52 week

Locations

Country Name City State
China Guangzhou Institute of Respiratory Diseases Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Guangzhou Institute of Respiratory Disease Boehringer Ingelheim

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Tiotropium Bromide Combined With Odaterol on endobronchial lumen area change difference in change from baseline in grade 7-9 endobronchial lumen area (Ai7-9) at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on mean bronchial diameter change difference in change from baseline in grade 7-9 mean bronchial diameter (Dmean7-9) at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on bronchial airway wall area change difference in change from baseline in grade 7-9 bronchial airway wall area (Aw and Aw% 7-9) at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on FEV1 change difference in change from baseline in trough FEV1 at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on SGRQ total score change difference in change from baseline in SGRQ (ST george's respiratory questionaire)total score at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on resonance frequency change difference in change from baseline in resonance frequency (Fres) at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on peripheral airway resistance change difference in change from baseline in peripheral airway resistance (R5-R20) at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on CAT total score change difference in change from baseline in CAT(Chronic obstructive pulmonary disease assessment test) total score at week 52 at week 52
Secondary Effect of Tiotropium Bromide Combined With Odaterol on mMRC total score change difference in change from baseline in mMRC(Modified British medical research council) total score at week 52 at week 52
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy